Vitiligo is a condition that causes loss of skin colour in patches due to the immune system attacking skin cells that produce melanin. It affects between 0.5% and 2% of the population and may be linked to other autoimmune diseases.
A new clinical trial is testing a monoclonal antibody – a targeted therapy designed to block the immune pathways that damage these cells.
By joining, you could:
- Try a potential new treatment not yet available outside research
- Receive specialist care and close monitoring
- Learn more about your condition
- Help develop safer, more effective treatments for people with vitiligo
Who can take part?
You may be eligible if you are:
- Over 18 years old
- Have been diagnosed with vitiligo for at least 3 months.
If you would like to learn more about this trial and possibly participate, please complete the application form below and we will be in touch.
